Arcutis Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARQT research report →
About the company
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis.
- CEO
- Todd Franklin Watanabe
- IPO
- 2020
- Employees
- 342
- HQ
- Westlake Village, CA, US
Price Chart
- Market Cap
- $3.23B
- P/E
- -1405.27
- P/S
- 7.77
- P/B
- 17.61
- EV/EBITDA
- 213.39
- Div Yield
- 0.00%
- Gross Margin
- 90.94%
- Op Margin
- 0.77%
- Net Margin
- -0.57%
- ROE
- -1.41%
- ROIC
- 1.05%
- Revenue
- $376.07M · 91.34%
- Net Income
- $-16,140,999 · 88.47%
- EPS
- $-0.13 · 88.79%
- Op Income
- $-12,227,000
- FCF YoY
- 94.38%
- 52W High
- $31.77
- 52W Low
- $13.06
- 50D MA
- $23.15
- 200D MA
- $24.42
- Beta
- 1.52
- Avg Volume
- 1.71M
Get TickerSpark's AI analysis on ARQT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | LIN SUE-JEAN | sell | 4,946 |
| Jun 15, 26 | Welgus Howard G. | other | 2,255 |
| Jun 15, 26 | Welgus Howard G. | other | 1,019 |
| Jun 15, 26 | Welgus Howard G. | other | 822 |
| Jun 15, 26 | Welgus Howard G. | sell | 4,096 |
| Jun 17, 26 | Welgus Howard G. | sell | 635 |
| Jun 15, 26 | Welgus Howard G. | other | 2,255 |
| Jun 15, 26 | Welgus Howard G. | other | 1,019 |
| Jun 15, 26 | Welgus Howard G. | other | 822 |
| Jun 5, 26 | Heron Patrick J | other | 0 |
Our ARQT coverage
Recent articles, reports, and earnings notes.
No research on ARQT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARQT report →Similar companies
Peers in the same neighborhood.